Cellceutix Responds to Public and Expedites Autism Drug Development!

Cellceutix continues to move forward with developments of KM-391, their compound for the treatment of autism. The press release states how they were able to pool some resources and expedite pre-clinical testing of KM-391. It appears that the word is out about a new treatment for autism being possible and the world is reaching out to Cellceutix and they are responding.

The second part of the press release is about the final piece of the puzzle to move forward towards the IND filing for Kevetrin. The time is near.

Cellceutix Responds to Public Support by Expediting Autism Studies; Completes Two Required Safety Pharmacology Studies for Its Cancer Compound

Press Release Source: Cellceutix On Monday June 7, 2010, 6:00 am EDT

BEVERLY, MA–(Marketwire – 06/07/10) – Cellceutix Corporation (OTC.BB:CTIX – News) is pleased to announce its acknowledgment of the many emails, phone calls and letters received regarding KM-391, its novel compound for the treatment of autism. Responding to the public’s requests, Cellceutix has drawn upon its many resources and expedited scheduling of additional pre-clinical studies of the compound with the results to be released in upcoming weeks.
Cellceutix worked in cooperation with the world-renowned InterEd Faculty of Clinical Research (IFCR) in India to move rapidly in the development of KM-391. The Company’s President and Chief Scientific Officer, Dr. Krishna Menon, as Chancellor of IFCR, was able to request expedited scheduling for the testing of KM-391. The prestigious Cochin University of Science & Technology (CUSAT) followed suit and conducted the testing. The research has been completed and the data is presently being analyzed and will soon be ready for release.

“Through a great collaborative effort between our team at Cellceutix with InterEd and Cochin University, we were able to reduce scheduling time from months to weeks,” commented George Evans, Chief Executive Officer of Cellceutix. “Our years of experience in the industry have provided us with valuable resources that were very supportive in our efforts to respond to the critical need for new autism treatments.”

The Company previously reported that initial testing conducted with KM-391 on a mouse model has provided promising data. In a carefully conducted study, KM-391 was given orally over 90 days to groups of rats at two dosage levels. At each dosage level, KM-391 demonstrated significant improvements in the test animals when compared to both the “no treatment” group and the “active control” (fluoxetine) group on the parameters of brain plasticity, serotonin levels and behavioral function. These parameters were selected as important indicators of the effect needed to successfully treat autism. Being that KM-391 is a novel compound and not merely a derivative of an existing compound, it is in the spotlight within the autism community and the focus of many communications to Cellceutix regarding its development.

Cellceutix Completes Two Required Safety Pharmacology Studies for its Cancer Compound, Kevetrin

Cellceutix Corporation also announces today that it has completed two animal safety pharmacology studies for its cancer compound, Kevetrin™, that are required by the U.S. Food and Drug Administration (FDA) prior to filing an Investigational New Drug (IND) application. These studies involve assessments of the impact of the administration of a compound on the respiratory and central nervous systems of test animals. In the respiratory study, respiratory rate, tidal volume and minute volume were measured. In the central nervous system study, neuropharmacological effects and effects on body temperature were measured. A cardiovascular safety pharmacology study is nearing completion.

“The results of these studies are very encouraging for the further development of Kevetrin,” said Dr. Krishna Menon, Chief Scientific Officer of Cellceutix. “The respiratory and central nervous system studies showed no biologically significant changes compared to controls. Since these studies are required by the FDA for an IND filing, their completion is a major forward step for us.”

About Cellceutix
Cellceutix Corporation is a preclinical cancer, autism and anti-inflammatory drug developer. Cellceutix owns the rights to eight drug compounds, including Kevetrin, which it is developing as a treatment for certain cancers, and KM-391, which it is developing for the treatment of autism. More information is available on the Cellceutix web site at

This Press Release contains forward-looking statements that are based on our current expectations, beliefs and assumptions about the industry and markets in which Cellceutix Corporation operates. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause Cellceutix’s actual results to be materially different from any future results expressed or implied by these statements. Actual results may differ materially from what is expressed in these statements, and no assurance can be given that Cellceutix can successfully implement its core business strategy and improve future earnings.
The factors that may cause Cellceutix’s actual results to differ from its forward-looking statements include: Cellceutix’s current critical need for additional cash to sustain existing operations and meet ongoing existing obligations and capital requirements; Cellceutix’s ability to implement its new product development and commercialization, enter into clinical trials, expand the intellectual property portfolio, and receive regulatory approvals in a timely and cost-effective manner. All forward-looking statements are also expressly qualified in their entirety by the cautionary statements included in Cellceutix’s SEC filings, including its quarterly reports on Form 10-Q and its annual report on Form 10-K.

Kevetrin and KM-391 have not been studied in humans at this time. The Company’s positive results in animal studies do not necessarily guarantee success in humans, though they may form the basis for beginning Phase 1 trials.

Cellceutix Corp.
Leo Ehrlich
(978) 633-3623


Add your comment

Commenting is allowed only for registered users.

Other articlesgo to homepage

Stocks Mixed on Monday

Stocks Mixed on Monday(0)

The Dow Jones industrial average topped 16,000 for the first time ever Monday, while the S&P 500 briefly surpassed 1,800. The Dow retreated from the 16,000 level, but still gained 14.32 points from Friday”s all-time high close, to 15,976. The S&P 500 index dipped 6.65 points to 1,791.53. The NASDAQ fell 36.90 points to 3,949.07

Cellceutix Targeting Gram-Negative and Candida Fungal Infections

Cellceutix Targeting Gram-Negative and Candida Fungal Infections(0)

Monday morning, Cellceutix Corp. (OTCQB: CTIX) provided shareholders with an update on its progress with filing an Investigational New Drug application with the FDA for its anti-psoriasis drug. Additionally – and taking the headline – the company delivered to shareholders news that it has made additional promising advancements with its pipeline to potentially address diseases

Catalyst Pharmaceutical Partners Stock Chart Analysis Video

Catalyst Pharmaceutical Partners Stock Chart Analysis Video(0)

The Catalyst Pharmaceutical Partners (NASDAQ: CPRX) stock chart formed a piercing line reversal pattern on Wednesday and Thursday that was confirmed with a sharp move upwards on Friday. Technical traders will be watching support around the 200 day moving average at $1.25 on any pullback, but for the time being, the chart looks to be

EnteroMedics Stock Chart Analysis Video

EnteroMedics Stock Chart Analysis Video(0)

The EnteroMedics (NASDAQ:ETRM) chart has been making higher highs and higher lows since forming a double bottom early in the year. The chart is holding over the 50-day moving average and inching higher each day as it tries to gain momentum to make the next leg up in the channel. EnteroMedics is a medical device

NXT-ID Authentication Using Face and Voice Recognition

NXT-ID Authentication Using Face and Voice Recognition(0)

There’s a Wocket in My Pocket! may soon not just be a sentence from the mouths of children after reading the rhyming book by Dr. Seuss. There was plenty of made-up ridiculousness in the iconic book, such as a bofa on the sofa, but there is nothing fictitious about the Wocket, a next-generation payment and

read more

Stay Informed

Receive the OTCS Newsletter *


* required

Dana-Farber to Host Cellceutix Trials

Cellceutix Corporation (CTIX)
Cellceutix Corporation has filed its Investigational New Drug application with the FDA. Dana-Farber and Beth Israel Deaconess Medical Center will be hosting the clinical trials for Kevetrin, Cellceutix's novel cancer drug. Read more news and get a stock quote.

Diabetes Rate Growing Exponentially

According to the International Diabetes Federation, more than 500 million people will be diagnosed with diabetes in the next two decades, a more than 50 percent increase from today. Technologies are available presently to help manage the frequency, complications and costs associated with diabetes. Read the complete article to learn more.

Contacts and information

Have an opinion or news that you want to share?

Social networks

Most popular categories

© 2011 Viper Enterprises, LLC. All rights reserved.